AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06490965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging (MRI) is a non-invasive medical imaging technique that generates detailed images of the internal structures of the body using a strong magnetic field and radio waves. It provides high-resolution images of soft tissues, such as organs, muscles, and the brain, helping doctors diagnose and monitor various conditions, including injuries, tumors, and neurological disorders. MRI is particularly useful because it does not involve ionizing radiation, making it safer for patients than other imaging methods like X-rays or CT scans.
Study NCT06490965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging (MRI) is a non-invasive medical imaging technique that generates detailed images of the internal structures of the body using a strong magnetic field and radio waves. It provides high-resolution images of soft tissues, such as organs, muscles, and the brain, helping doctors diagnose and monitor various conditions, including injuries, tumors, and neurological disorders. MRI is particularly useful because it does not involve ionizing radiation, making it safer for patients than other imaging methods like X-rays or CT scans.
Study NCT03610542 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identifying and challenging negative thoughts
Description: Students learn about the types of unrealistic thoughts that underpin anxiety and how anxiety can be reduced with more realistic thoughts. Students identify their own unrealistic thoughts that contribute to anxiety and what more realistic thoughts can be used.
Study NCT03610542 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation
Description: Students are taught to relax through (1) breathing exercises, (2) progressive muscle relaxation, and (3) imagery. Student practice these techniques.
Study NCT03610542 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Setting
Description: Students learn how to set goals, monitor goal progress, and check when goals have been achieved. Students then identify their own goals.
Study NCT03610542 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overcoming avoidance
Description: Students identify ways that they avoid anxiety-provoking situations (e.g., procrastinating exam study). Students develop plans for exposure to anxiety-provoking situations and learn study strategies to build confidence.
Study NCT04193150 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Full pulmonary specialist assessment
Description: Please see description for the intervention arm.
Study NCT04980183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arthroscopic surgical robot
Description: The surgeon performs cruciate ligament bone canal positioning and ligament reconstruction with the assistance of an arthroscopic surgical robot
Study NCT04980183 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional arthroscopic cruciate ligament reconstruction
Description: The surgeon performs conventional arthroscopic cruciate ligament reconstruction surgery without other auxiliary equipment
Study NCT05386433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxlovid
Description: Paxlovid contains two medicines: nirmatrelvir and ritonavir. Nirmatrelvir \[PF-07321332\] is a SARS-CoV-2 main protease (Mpro) inhibitor (also known as SARS-CoV2 3CL protease inhibitor) that works by inhibiting viral replication in the early stages of the disease to prevent progression to severe COVID-19.~Ritonavir is co-administered with nirmatrelvir to help slow its metabolism in order for it to remain active in the body for longer periods of time at higher concentrations to help combat the virus.
Study NCT05983783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: This is Triple drug regimen for mHSPC
Study NCT05983783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rezvilutamide
Description: This is doubling drug regimen for mHSPC
Study NCT05786118 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this study
Study NCT06274762 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training and BSE application on a model
Description: A breast cancer awareness training designed according to the headings of sensitivity, seriousness, benefit, obstacle perception, health motivation and self-efficacy, which are the steps of the health belief model, followed by applied BSE on a model.
Study NCT06274762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training and BSE application on a model
Description: A breast cancer awareness training designed according to the headings of sensitivity, seriousness, benefit, obstacle perception, health motivation and self-efficacy, which are the steps of the health belief model, followed by applied BSE on a model.
Study NCT06353139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified olfactory training device
Description: Conduct olfactory training in patients with olfactory disorders
Study NCT06353139 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified olfactory training device
Description: Conduct olfactory training in patients with olfactory disorders
Study NCT05386433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: standard-of-care
Description: standard-of-care of COVID-19
Study NCT05386433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard-of-care
Description: standard-of-care of COVID-19
Study NCT04526977 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immune response study
Description: * ACE2 and CD26 receptor study~* Cytokine profile: Quantification of plasma cytokine levels~* SARS-CoV-2 CD4/CD8 T cell response~* TLR7/8 activation~* KIR characterization
Study NCT05098223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to remove price promotions on unhealthy foods when online shopping
Description: Removal of price promotions on unhealthy foods
Study NCT00240773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: 4 grams daily for six months
Study NCT00240773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: 750 mg daily for 12 months
Study NCT00240773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: 4 grams daily for 12 months
Study NCT00240773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: 750 mg daily for six months
Study NCT04444297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D Telemedicine
Description: A consultation performed with a 3D form of telemedicine
Study NCT04444297 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2D Telemedicine
Description: A consultation performed with 2D (standard) telemedicine
Study NCT06523751 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trabeculopuncture
Description: Trabeculopuncture is performed with a Nd:YAG laser on the trabecular meshwork. Four punctures are created along the 180° nasal trabecular meshwork.
Study NCT04828876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga practice
Description: Yoga basically consists of breathing techniques, asanas (postures) and relaxation phases.~Practiced Yoga Stages; 10 min. standing breathing exercise, 10 min. breathing exercise with seated asana, 10 min. lying down breathing exercise with asana, 20 min. sitting breathing exercise, 10 min. The session will be completed in 60 minutes, including deep relaxation stages by lying down. At the end of each session, patients' feedback about yoga practice will be received.
Study NCT05074784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOPI Therapy
Description: Obtain IOPI reading at start of session, record the best of 3 readings as baseline strength. Calculate exercise resistance for session at 60% of baseline strength. Using the IOPI, participants will perform 24 sets of 5 repetition at anterior position, allowing for 30 secs rest in between sets.
Study NCT05074784 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tongue Depressor Traditional Intervention
Description: Using the tongue depressor, participants will be prompted to stick their tongue out as much as they can and to push hard against the tongue depressor for 10 seconds. They will be required to repeat this action 10 times, constituting one set. They will be asked to perform 3 sets, with 30 secs of rest between each set
Study NCT05418920 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: left-opening single-flap technique
Description: left-opening single-flap technique
Study NCT05418920 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: double-flap group technique
Description: double-flap group technique
Study NCT05717920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-629 (Open-label)
Description: ADX-629 (250 mg) administered twice daily for 90 days
Study NCT05464277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Oxygen to achieve assigned SpO2 (or FiO2) targets will be administered to study subjects. The treating clinician can alter oxygenation targets at any time if deemed necessary. The oxygenation goal will be based on SpO2 rather than arterial oxygen saturation (SaO2) or arterial pressure oxygen (PaO2) from arterial blood gases. However, PaO2 can be used instead in situations where the treating clinician considers that peripheral perfusion is poor or SpO2 readings are unreliable. Assigned SpO2 targets will apply to the study subjects for a total duration of 6 hours from intubation or until death or until transfer to the operating theater (whatever comes first).
Study NCT06401733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Aerobic and Resistance Exercise Program (IAREP)
Description: IAREP is a combined aerobic exercise and resistance training program that developed by qualified exercise professionals. It encompasses a 12-week exercise intervention, conducted in a blended mode which consists of face-to-face exercise, Zoom exercise, and pre-recorded video exercise.~Frequency: 3 times exercise per week. Intensity: moderate to vigorous exercise. Time of the exercise: 45-60 mins. Type of exercise: combined aerobic and resistance training.~Warm-up: aerobic workout with dynamic stretch (for targeted muscles). Aerobic exercise: each session encompasses 5 exercise. Resistance training: each session encompasses 4 exercise, 2 upper body exercise and 2 lower body exercise.~Cool-down: relax targeted muscles.
Study NCT05538130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07799544
Description: Tablet
Study NCT05538130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07799933
Description: Tablet
Study NCT04686487 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: stereotactic ablative radiotherapy
Description: stereotactic ablative radiotherapy by targeting high energy heavy ion beams at a specific area of the body
Study NCT03663153 — intervention group
Intervention type: OTHER
Intervention: SEMA4C high value follow-up group
Description: Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
Study NCT03663153 — intervention group
Intervention type: OTHER
Intervention: SEMA4C low value follow-up group
Description: Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
Study NCT04648501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task training
Description: Dual-task (CIBT- experimental) group participants will receive 10 minutes of warm up, 40 minutes of CIBT training and 10 minutes of cool down exercises. CIBT program includes performing four types of cognitive tasks during sit to stand, standing with feet apart, one leg, tandem standing, multidirectional reaching, stair climbing and walking (10 metres) tasks. The four cognitive tasks will include: counting backwards by subtracting 4 numbers (for mental tracking ), naming fruits, vegetables, or animals (for working memory), auditory cues for performing activities, example, perform heel raise when you hear the alphabet H (for improving attention and auditory discrimination), short story telling (for verbal fluency). In addition, falls prevention strategies will be taught.
Study NCT04648501 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual-task training
Description: Dual-task (CIBT- experimental) group participants will receive 10 minutes of warm up, 40 minutes of CIBT training and 10 minutes of cool down exercises. CIBT program includes performing four types of cognitive tasks during sit to stand, standing with feet apart, one leg, tandem standing, multidirectional reaching, stair climbing and walking (10 metres) tasks. The four cognitive tasks will include: counting backwards by subtracting 4 numbers (for mental tracking ), naming fruits, vegetables, or animals (for working memory), auditory cues for performing activities, example, perform heel raise when you hear the alphabet H (for improving attention and auditory discrimination), short story telling (for verbal fluency). In addition, falls prevention strategies will be taught.
Study NCT04508764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Families Accelerating Cascade Testing Toolkit
Description: -Online family history assessment, video of Siteman Cancer Center genetic counselors, physicians and patients highlighting the importance of cascade genetic testing, reviewing and receiving a family letter and gene information sheet, reviewing websites/online resources, and offering a family visit with a genetic counselor
Study NCT05538130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib
Description: Capsule
Study NCT05706675 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical periodontal therapy
Description: Manual root planning+Ultrasonic subgingival debridement
Study NCT05993871 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve Conduction Study
Description: Routine Nerve Conduction Study.
Study NCT05993871 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Small fiber electrodiagnostic tests
Description: R-R interval analysis, Cutaneous Silent Period and Sympathetic Skin Response.
Study NCT05993871 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve Ultrasound
Description: Bilateral vagal, left median, right ulnar, left tibial and right sural nerves ultrasound.
Study NCT04262427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 50mg
Description: cytotoxic chemotherapy
Study NCT04262427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]
Description: potent humanized immunoglobulin (Ig) G4 monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor
Study NCT06207227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VITA AV Clinical System
Description: The VITA AV Clinical System that works on the principle of negative pressure suction to the vaginal wall to treat VA, based on the idea of the clinical application in wound healing which is intended to elicit improvements in the rate of angiogenesis, moisture and HA production post-treatment. It is believed that the VITA AV Clinical System will provide a more effective treatment by improving the underlying cellular deficiencies associated with VA.
Study NCT05738616 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib combined with TACE and Camrelizumab
Description: Once subjects have signed the informed consent and passed screening, they will be randomized in a 1:1 ratio to either the experimental arm (lenvatinib combined with TACE and camrelizumab) or the control arm (lenvatinib combined with TACE).
Study NCT05738616 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lenvatinib combined with TACE and Camrelizumab
Description: Once subjects have signed the informed consent and passed screening, they will be randomized in a 1:1 ratio to either the experimental arm (lenvatinib combined with TACE and camrelizumab) or the control arm (lenvatinib combined with TACE).
Study NCT05993871 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Skin Biopsy
Description: distal leg 3mm punch skin biopsy
Study NCT05420012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat
Description: A starting dose of vericiguat 2.5 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Subjects will be up-titrated in a blinded fashion to 5 mg and then to the target dose of 10 mg of vericiguat or matching placebo using titration criteria based on mean systolic blood pressure(SBP) evaluation and clinical symptoms at 2 week intervals. Titration to 10 mg in subjects who have not yet reached the target dose is intended at every visit/phone call throughout the study duration based on mean SBP measurement and safety considerations, at the discretion of the investigator.
Study NCT05420012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A starting dose of vericiguat 2.5 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Subjects will be up-titrated in a blinded fashion to 5 mg and then to the target dose of 10 mg of vericiguat or matching placebo using titration criteria based on mean systolic blood pressure(SBP) evaluation and clinical symptoms at 2 week intervals. Titration to 10 mg in subjects who have not yet reached the target dose is intended at every visit/phone call throughout the study duration based on mean SBP measurement and safety considerations, at the discretion of the investigator.
Study NCT05980026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral omega-3 fatty acids supplementation
Description: oral omega-3 fatty acids supplementation
Study NCT05980026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in placebo group received placebo that were similar in appearance to omega 3 fatty acids and the administered dose was as the same schedule as omega 3 fatty acids.
Study NCT05657977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nonpharmacologic intervention (swaddling)
Description: Swaddling method;The newborn will be placed on a square fabric blanket in the flexion and abduction position and will be loosely swaddled with a blanket.
Study NCT04859127 — intervention group
Intervention type: OTHER
Intervention: effects of neck pain
Description: Within the scope of the evaluation for the assessment of pain by visual analog scale (VAS), standard evaluation posture Postural Analysis, range of motion for the evaluation of Elektrogonyometer, Nov stabilizer and force evaluation for a hand-held Dynamometer, Nov for brevity, brevity reviews left internal rotator muscles of the pectoral muscles with standard, fear of movement kinezyofobi Tampa scale for the assessment of the neck in apology, questioning of the status of the inquiry Neck Disability Survey, stars in the evaluation of balance dynamic balance test, stand on one leg Test in the evaluation of static balance, dynamic balance and physical performance Term rise and walk test, gait speed for the assessment of the 10-meter walk test and dual-task for the evaluation of the motor-the motor and motor-Cognitive dual-task will be used for the evaluation.
Study NCT05259540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: compound kushen injection combined with pabolizumab
Description: compound kushen injection 20ml/day and pabolizumab 200mg/21 days, both drugs are given intravenously
Study NCT05417386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion
Study NCT05417386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion
Study NCT05417386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion
Study NCT05417386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion
Study NCT05417386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion
Study NCT05417386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIS793
Description: Given by intravenous infusion
Study NCT05417386 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: Combination of Chemo (Capecitabine) and Radiation Therapy
Study NCT05417386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Taken Orally as part of Chemoradiation
Study NCT05417386 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation Therapy as part of Chemoradiation
Study NCT05417386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical removal of tumor